Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.33, $0.11 better than the analyst estimate of $1.22. Revenue for the quarter came in at $45.33 million versus the consensus estimate of $37.92 million.

GUIDANCE:

Ligand Pharma sees FY2025 EPS of $6.00-$6.25, versus the consensus of $6.11. Ligand Pharma sees FY2025 revenue of $180-200 million, versus the consensus of $191.3 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.